Baseline sampling [Regulatives / Guidelines]

posted by NK – India, 2019-06-26 07:25 (723 d 22:53 ago) – Posting: # 20360
Views: 2,370

Hello everyone,

I have a question with regards to FDA OGD guidance of Dihydroergotamine Nasal Spray" dated February 2019.

The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

As per my understanding, Dihydroergotamine is neither endogenous nor available in the diet, then why baseline value is required?

If it is required, what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

Thanks in advance.


Edit: URL corrected. [Helmut]

Complete thread:

 Admin contact
21,529 posts in 4,499 threads, 1,523 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Saturday 06:18 CEST (Europe/Vienna)

Anyone who has never made a mistake
has never tried anything new.    Albert Einstein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz